Radioimmunoassay of blood bradykinin: purification of blood extracts to prevent cross-reaction with endogenous kininogen

Leeuwen, B. H. van; Millar, J. A.; Hammat, Marianne T.; Johnston, Colin I.

doi:10.1016/0009-8981(83)90161-4

Cited by 10 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this failure to observe consistent increases in bradykinin levels may reflect methodological differences in measuring bradykinin levels in blood (van Leeuwen et al, 1983) or be a consequence of increased activity in alternative metabolic degradative pathways, an alternative explanation is that circulating levels may not reflect increased local tissue levels of kinins (Johnston et al, 1982;Odya et al, 1983) and the absence of a measurable effect on circulating levels does not mean that such an effect is not part of the mechanism of action of a converting enzyme inhibitor.…”

Section: Discussionmentioning

confidence: 99%

A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

Cooke

Turner

1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. The effects of captopril and enalapril on skin responses to intradermal injections of bradykinin and skin blood flow in the forearm were investigated in this randomised, double‐blind, placebo‐controlled, cross‐over study. 2. Intradermal injections of 0, 1, 2.5 and 5 micrograms of bradykinin in 0.9% sodium chloride were made into the forearm of twelve healthy volunteers before and at 2, 6 and 24 h after single oral doses of 25 mg captopril, 10 mg enalapril or placebo. Forearm skin blood flow was measured by the technique of laser Doppler flowmetry (LDF) before the injections were made and the skin responses evaluated at 15 min after injections of bradykinin by measurement of cutaneous blood flow outside the induced weal, erythema area and weal volume. 3. The bradykinin‐induced cutaneous responses measured by LDF, erythema area and weal volume increased with incremental bradykinin dose. Compared with placebo, captopril significantly augmented the cutaneous vasodilator effects of bradykinin, measured by LDF and erythema area, at 2 h and the weal responses at 2 and 6 h. Enalapril enhanced the vasodilator responses to bradykinin at 2 and 6 h and the weal responses at 2, 6 and 24 h. Neither captopril nor enalapril significantly affected forearm skin blood flow. 4. This study showed that captopril and enalapril potentiated the effects of intradermal bradykinin both with respect to blood flow changes and weal formation in keeping with effective kininase II inhibition and the time course of these changes are consistent with enalapril being a longer acting drug than captopril. Captopril and enalapril exerted no influence on forearm skin blood flow measured by LDF.

show abstract

Section: Discussionmentioning

confidence: 99%

A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

Cooke

Turner

1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…al.. Published radioimmunoassays (RIAs) [10][11][12]16,18] predominantly use organic solvent precipitation and extraction of the samples. Earlier reports [18] without enzyme inhibitors have reported blood kinin concentrations of up to 460 ng/ml, while following studies with different inhibitor mixes [10,12,16] claim bradykinin concentrations of 0.2-7 pmol/l in healthy controls.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…Due to the pre-analytical challenges of preserving the intact peptide, some laboratories have instead opted to assay bradykinin metabolites such as bradykinin 1-5 (BK(1-5)), a pentapeptide fragment of bradykinin, which is considered more stable [9]. Another issue encountered with immunochemical assays is that the antibodies used may exhibit some cross-reactivity for the precursors and metabolites of bradykinin [10,11].…”

Section: Introductionmentioning

confidence: 99%

Plasma bradykinin concentrations during septic shock determined by a novel LC-MS/MS assay

Lindström

Valkonen

Tohmola

et al. 2019

Clinica Chimica Acta

View full text Add to dashboard Cite

Background: Bradykinin is an important mediator of inflammation and vascular permeability and could have an important role in the development of septic shock. Measurement of bradykinin by immunological methods may suffer from interference and lack of specificity. We developed and validated a liquid chromatography mass spectrometry assay (LC-MS/MS) for plasma bradykinin.Methods: We used plasma samples from healthy volunteers (n=19) and patients with septic shock (n=47).Stable isotope bradykinin internal standard was added to samples before solid-phase extraction and quantification by LC-MS/MS. Stability of bradykinin was studied for 12 months.Results: Our assay has good sensitivity (0.1 nmol/l) and a wide linear range (0.1-1000 nmol/l). Bradykinin added to plasma was stable for 12 months at -20 °C when a mixture of protease inhibitors was added at sampling but degraded during repeated freezing and thawing. Bradykinin concentration in plasma from septic shock patients (<0.1-0.6 nmol/l) did not change significantly during shock and recovery but differed slightly from that in healthy individuals (0.5-1.1 nmol/l).Conclusions: Our bradykinin assay was successfully used to determine bradykinin concentrations in plasma samples. Intensive care unit patients with septic shock had low concentrations of plasma bradykinin during both shock and recovery phases.

show abstract

“…The immediate fall in blood pressure after the initial dose of the orally active inhibitor captopril has been shown by of ACE inhibitors is a matter of controversy (16,17). This lack of consensus arises mainly from the methodological problems in determining bradykinin in biological fluids (18)(19)(20).…”

mentioning

confidence: 99%

Converting Enzyme Inhibition in Mild and Moderate Essential Hypertension: I. Acute Effects on Blood Pressure, the Renin‐Angiotensin System and Blood Bradykinin after a Single Dose of Captopril

Rasmussen

Leth

Ibsen

et al. 1985

Journal of Internal Medicine

View full text Add to dashboard Cite

Converting enzyme inhibition in mild and moderate essential hypertension. I. Acta Med Scand 1985; 218: 435-42.some authors to be proportional to the prevailing plasma concentrations of angiotensin I1 (4-7), whereas others have failed to find such a relationship (8,9). Maintenance therapy often leads to further reductions in blood pressure which in some studies have been shown to be correlated to the pretreatment levels of angiotensin I1 or renin (10-12), but not in others (7,9,(13)(14)(15). The evidence for involvement of bradykinin in the hypotensive action Abbreviations: ACE = angiotensin converting enzyme, PRC = plasma concentration of renin, PRSC = plasma concentration of renin substrate, PA1 = plasma concentration of angiotensin I, PA11 = plasma concentration of angiotensin 11, BBK = blood concentration of bradykinin, DBP = diastolic blood pressure, MAP = mean arterial pressure, HR = heart rate.

show abstract

Radioimmunoassay of blood bradykinin: purification of blood extracts to prevent cross-reaction with endogenous kininogen

Cited by 10 publications

References 17 publications

A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

Plasma bradykinin concentrations during septic shock determined by a novel LC-MS/MS assay

Converting Enzyme Inhibition in Mild and Moderate Essential Hypertension: I. Acute Effects on Blood Pressure, the Renin‐Angiotensin System and Blood Bradykinin after a Single Dose of Captopril

Contact Info

Product

Resources

About